Cardiorenal Medicine最新文献

{"title":"Association of Uric Acid to High-Density Lipoprotein Cholesterol Ratio with Left Ventricular Hypertrophy in Chronic Kidney Disease.","authors":"Li Wang, Fangfang Xiang, Jun Ji, Lin Zhang, Xiaotian Jiang, Yi Fang, Xiaoqiang Ding, Wuhua Jiang","doi":"10.1159/000545822","DOIUrl":"10.1159/000545822","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic kidney disease (CKD) is associated with a high prevalence of cardiovascular complications, including left ventricular hypertrophy (LVH), which significantly increases morbidity and mortality. LVH in CKD results from a complex interplay of hemodynamic, neurohormonal, and metabolic factors. The uric acid-to-high density lipoprotein cholesterol ratio (UHR) has recently been proposed as a potential marker for cardiovascular outcomes, combining the effects of uric acid and HDL-C on inflammation and cardiovascular risk. However, the relationship between UHR and LVH in CKD patients remains unexplored. This study aimed to investigate the association between UHR and LVH in patients with CKD.</p><p><strong>Methods: </strong>This cross-sectional study included CKD patients admitted to the Division of Nephrology between April 2019 and October 2019. CKD was staged according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. LVH was assessed using transthoracic echocardiography, and left ventricular mass index (LVMI) was calculated. LVH was defined as an LVMI >115 g/m2 for men and >95 g/m2 for women. UHR was calculated by dividing serum uric acid levels (µmol/L) by HDL-C levels (mmol/L). Multivariable logistic regression models were used to assess the association between UHR and LVH, adjusting for covariates including age, gender, BMI, and other relevant clinical factors.</p><p><strong>Results: </strong>A total of 466 patients were included, of whom 56 had LVH. Patients with LVH had significantly higher UHR levels compared to those without LVH. In multivariable regression analysis, the natural logarithm of UHR (LnUHR) was significantly associated with an increased risk of LVH (OR: 2.04, 95% CI: 1.05-4.12, p = 0.035) after full adjustment for confounders. Further analysis using restricted cubic splines revealed a non-linear relationship between UHR and LVH, with an inflection point at UHR = 0.60. Below this threshold, each increase of one standard deviation in UHR was associated with a 2.11-fold increase in LVH risk (OR: 2.11, 95% CI: 1.51-3.03, p < 0.001), while above this threshold, the association was not significant (OR: 0.82, 95% CI: 0.39-1.47, p = 0.54).</p><p><strong>Conclusion: </strong>This study provides the first evidence of an association between UHR and LVH in CKD patients, particularly at lower UHR levels. The findings suggest that UHR could serve as a novel marker for cardiovascular risk stratification in CKD, reflecting the balance between pro-inflammatory and protective cardiovascular factors. These results highlight the potential of UHR as a cost-effective tool for identifying CKD patients at increased risk of LVH, warranting further investigation in longitudinal studies to establish causality and explore targeted interventions.</p>","PeriodicalId":9584,"journal":{"name":"Cardiorenal Medicine","volume":" ","pages":"323-332"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143974938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blood Pressure Variability in Older Patients with Chronic Kidney Disease.","authors":"Davi Wei Ming Wang, Bruna Cristine D Rodrigues, Maria Eugenia Canziani, Gabriel Merli, Helena Souza, Julia de Toledo Martins, Wilson Jacob-Filho, Roberto Zatz, Rosa M A Moysés, Fernanda Marciano Consolim-Colombo, Rosilene M Elias","doi":"10.1159/000545403","DOIUrl":"10.1159/000545403","url":null,"abstract":"<p><strong>Background: </strong>An increased blood pressure variability (BPV) is associated with a high risk of cardiovascular events in the general population. This concept was scarcely tested in patients with chronic kidney disease (CKD). We investigated the behavior of BPV parameters in a large cohort of older patients with CKD.</p><p><strong>Methods: </strong>This retrospective cohort study included patients ≥75 years old with eGFR ≤60 mL/min. Three systolic and diastolic consecutive blood pressure (BP) measurements were obtained automatically per visit (short term - 3 consecutive measurements) and across visits (long term - across visits). We calculated (1) standard deviation (SD); (2) coefficient of variation (SD divided by the BP average); and (3) variability independent of the mean (VIM). For each BPV parameter, patients were divided into quartiles.</p><p><strong>Results: </strong>We included 1,063 patients (17,363 measurements). For short BPV, the higher systolic BPV (SD and VIM) was associated with older age, a lower proportion of males, and a higher proportion of patients with pulse pressure (PP) >40 mm Hg. Higher diastolic BPV (SD and VIM) was associated with lower body mass index, lower eGFR, and a higher proportion of PP >40 mm Hg (for SD). Bland-Altman plots revealed comparable results between short- and long-term BPV.</p><p><strong>Conclusion: </strong>A higher BPV was associated with reduced renal function in older patients with CKD. Our study also suggests that short- and long-term BPV can be used with similar results. Further studies are needed to confirm the association between BPV and outcomes and understand the physiological mechanisms underlying this correlation.</p>","PeriodicalId":9584,"journal":{"name":"Cardiorenal Medicine","volume":" ","pages":"347-357"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143973921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inflammation and Arterial Stiffness as Drivers of Cardiovascular Risk in Kidney Disease.","authors":"Lorenzo Lo Cicero, Paolo Lentini, Concetto Sessa, Niccolò Castellino, Ambra D'Anca, Irene Torrisi, Carmelita Marcantoni, Pietro Castellino, Domenico Santoro, Luca Zanoli","doi":"10.1159/000542965","DOIUrl":"10.1159/000542965","url":null,"abstract":"<p><strong>Background: </strong>Patients with chronic kidney disease (CKD) have an increased cardiovascular (CV) risk. The lower the glomerular filtration rate, the higher the CV risk.</p><p><strong>Summary: </strong>Current data suggest that several uremic toxins lead to vascular inflammation and oxidative stress that, in turn, lead to endothelial dysfunction, changes in smooth muscle cells' phenotype, and increased degradation of elastin and collagen fibers. These processes lead to both functional and structural arterial stiffening and explain part of the increased risk of acute myocardial infarction and stroke reported in patients with CKD. Considering that, at least in patients with end-stage kidney disease, the reduction of arterial stiffness is associated with a parallel decrease of the CV risk; vascular function is a potential target for therapy to reduce the CV risk.</p><p><strong>Key messages: </strong>In this review, we explore mechanisms of vascular dysfunction in CKD, paying particular attention to inflammation, reporting current data in other models of mild and severe inflammation, and discussing the vascular effect of several drugs currently used in nephrology.</p>","PeriodicalId":9584,"journal":{"name":"Cardiorenal Medicine","volume":" ","pages":"29-40"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11844711/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142779401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A New Clinical Entity Bridging the Cardiovascular System and the Kidney: The Chronic Cardiovascular-Kidney Disorder.","authors":"Carmine Zoccali","doi":"10.1159/000542628","DOIUrl":"10.1159/000542628","url":null,"abstract":"<p><strong>Background: </strong>The complex relationship between heart and kidney dysfunction has been a subject of medical inquiry since the 19th century. The term \"cardio-renal syndrome\" (CRS) was introduced in the early 2000s and has since become a focal point of research. CRS is typically categorized into five subtypes based on the sequence of cardiovascular and kidney disease events.</p><p><strong>Summary: </strong>The cardiovascular-kidney-metabolic (CKM) syndrome, as defined by the American Heart Association, describes a set of interrelated metabolic risk factors and their effects on the kidneys and cardiovascular system. This syndrome emphasizes the complexity of managing patients with combined conditions and identifies several knowledge gaps, including disease mechanisms, clinical phenotype variability, and the impact of social determinants of health. The chronic cardiovascular-kidney disorder (CCKD) framework proposes a shift from the term \"syndrome\" to \"disorder,\" focusing on concurrent cardiovascular and kidney problems regardless of their sequence.</p><p><strong>Key messages: </strong>(i) The CCKD concept calls for simplification and conceptual clarity, arguing that understanding the bidirectional acceleration of disease progression between heart and kidney dysfunction can lead to more effective treatment strategies. (ii) Both CKM and CCKD share common pathophysiological mechanisms and risk factors, including hypertension, diabetes, obesity, and dyslipidemia. Managing these conditions requires a comprehensive approach that addresses the underlying risk factors and pathophysiological mechanisms. (iii) Future directions include embracing precision medicine, public health strategies, interdisciplinary care models, and ongoing research and innovation. Both frameworks underscore the need for comprehensive, interdisciplinary care models and innovative treatment strategies to address the complex interplay between cardiovascular and kidney diseases.</p>","PeriodicalId":9584,"journal":{"name":"Cardiorenal Medicine","volume":" ","pages":"21-28"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11844677/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global Longitudinal Strain Correlates Poorly with Mortality in People with Diabetes Mellitus and Receiving Haemodialysis.","authors":"Saif Al-Chalabi, Sally Alezergawi, Darren Green, Smeeta Sinha, Philip A Kalra","doi":"10.1159/000542964","DOIUrl":"10.1159/000542964","url":null,"abstract":"<p><strong>Introduction: </strong>Haemodialysis (HD) is a life-sustaining treatment for individuals with end-stage kidney disease. However, the risk of mortality remains significantly higher compared to the general population, even when matched for age and sex. Global longitudinal strain (GLS), derived from speckle tracking echocardiography, has shown promise as a predictor of mortality in HD patients. However, its prognostic utility in patients with multiple cardiovascular risk factors such as diabetes mellitus (DM) and receiving HD remains unclear. This study aimed to evaluate the prognostic value of GLS in HD patients, with and without DM.</p><p><strong>Methods: </strong>This prospective study was a long-term follow-up extension study of an earlier published study that investigated a cohort of HD patients from a single centre with a comprehensive cardiovascular imaging protocol. All patients had an echocardiography with the use of speckle tracking software to determine GLS. Patients were divided into group A (with DM) and group B (without DM). Patients were followed up until death, major adverse cardiovascular events, transplantation, or the censoring date (29 February 2024). Statistical analyses were performed using univariate and multivariate Cox proportional hazards models.</p><p><strong>Results: </strong>A total of 184 patients receiving HD were included in the analysis. Patients with DM (group A) had significantly higher all-cause mortality (ACM) (47.1% vs. 20.7%, p < 0.001) and a lower chance of receiving a kidney transplant (13.2% vs. 43.1%, p < 0.001). In group A, GLS did not predict ACM, whereas in group B, a GLS cut-off of -15.76% correlated with higher 5-year ACM (p = 0.036). Left ventricular ejection fraction (LVEF) was a significant predictor of ACM in group A (HR 0.98; p = 0.036).</p><p><strong>Conclusion: </strong>GLS is a poor predictor of adverse outcomes in HD patients with DM, likely due to their high cardiovascular risk. In contrast, GLS was a significant predictor of mortality in non-diabetic HD patients. LVEF may be a more reliable prognostic indicator in high-risk diabetic patients.</p>","PeriodicalId":9584,"journal":{"name":"Cardiorenal Medicine","volume":" ","pages":"61-71"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11844706/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142766612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pulsatile Arterial Haemodynamic Effect on Renal Outcomes in Patients with Acute Heart Failure.","authors":"François Croset, Pau Llàcer, Jorge Campos, Marina García-Melero, Carlos Pérez, Alberto Pérez-Nieva, Raúl Ruiz, Daniel Useros, Cristina Fernández, María Pumares, Almudena Vázquez, Esteban Pérez-Pisón, Martín Fabregate, Luis Manzano","doi":"10.1159/000547430","DOIUrl":"10.1159/000547430","url":null,"abstract":"<p><strong>Introduction: </strong>Haemodynamic changes in acute heart failure (AHF) are closely linked to renal function alterations. Pulse pressure (PP) may offer insights beyond mean arterial pressure in identifying patients with vulnerable renal function during AHF episodes. This study aimed to investigate the association between PP and renal function parameters, including urinary albumin-creatinine ratio (UACR) and changes in creatinine, in patients hospitalized for AHF.</p><p><strong>Methods: </strong>We conducted a retrospective observational study involving 695 patients admitted for AHF between June 2020 and April 2023. PP was calculated at admission, and renal function parameters were assessed over the first 48 h. A multivariable linear regression assessed the association between PP and UACR and creatinine changes, adjusting for possible confounders.</p><p><strong>Results: </strong>Patients in the highest tertile of PP exhibited a significantly higher incidence of worsening renal function (p = 0.048) and a lower incidence of improved renal function (p = 0.001). Multivariable analysis identified PP as an independent predictor of changes in creatinine (p = 0.010) and UACR (p = 0.037). The findings suggest that elevated PP may indicate impaired renal autoregulation and an increased risk of renal deterioration during AHF.</p><p><strong>Conclusion: </strong>In patients hospitalized for AHF, PP showed a positive and linear association with UACR values and changes in creatinine during the first 48 h of intravenous furosemide treatment. PP may help identify patients with kidneys more susceptible to haemodynamic changes during hospitalization for AHF.</p>","PeriodicalId":9584,"journal":{"name":"Cardiorenal Medicine","volume":" ","pages":"587-594"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144854700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiorenal Benefits of SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Concomitant Hypertension.","authors":"Mi Wang, Li Zuo","doi":"10.1159/000545622","DOIUrl":"10.1159/000545622","url":null,"abstract":"<p><strong>Background: </strong>Uncontrolled hypertension is both a driver of chronic kidney disease (CKD) and a complication of the disease, as well as a risk factor for cardiovascular disease (CVD). Therefore, renal protective agents with antihypertensive properties are desirable for management of cardiorenal syndrome in CKD. Sodium-glucose cotransporter-2 (SGLT2) inhibitors are emerging as a new class of renal protective agents, with robust efficacy in delaying progression of CKD and reducing cardiovascular events. Here, we present an overview of SGLT2 inhibitors and discuss the alternative mechanisms contributing to the antihypertensive and cardiorenal benefits of SGLT2 inhibitors, with a focus on people with CKD and concomitant hypertension. We also explore the role of SGLT2 as a central node in the pathways underlying these mechanisms.</p><p><strong>Summary: </strong>Beyond its well-known renal benefit, SGLT2 inhibitors have shown blood pressure (BP)-lowering effects in people with CKD, with an average reduction of 3-5 mm Hg in systolic BP. Clinical evidence has shown that SGLT2 inhibitors confer cardiorenal protective effects in patients with CKD regardless of diabetes status, and these benefits appear to extend to individuals with hypertensive CKD. The antihypertensive effects of SGLT2 inhibitors were also demonstrated in patients with CKD and hypertension. While osmotic diuresis is thought to be a predominant mechanism underlying the antihypertensive effects of SGLT2 inhibitors in the CKD population, we believe that the underlying mechanisms are likely to be multifactorial, with alternative pathways also involved, particularly in hypertension-associated CKD.</p><p><strong>Key messages: </strong>Given the rising incidence of hypertension and CKD, the BP-lowering and cardioprotective effects of SGLT2 inhibitors could provide additional value in using this drug class for management of patients with CKD who have hypertension. Further subgroup analyses or larger studies on this specific population will provide more insights into the role of SGLT2 inhibitors in improving cardiorenal outcomes in this setting.</p>","PeriodicalId":9584,"journal":{"name":"Cardiorenal Medicine","volume":" ","pages":"496-509"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Uncovering Candidate Genes Associated with Cardiovascular Disease in Patients with Arteriovenous Fistula and End-Stage Renal Disease.","authors":"Guoxin Zhang, Jieqiong Fu, Limin Nie","doi":"10.1159/000546299","DOIUrl":"10.1159/000546299","url":null,"abstract":"<p><strong>Background: </strong>The molecular association between end-stage renal disease (ESRD), arteriovenous fistula (AVF) failure, and cardiovascular disease (CVD) remains unclear. This study aimed to investigate their potential relationship.</p><p><strong>Methods: </strong>Three datasets were downloaded from the public database. AVF-failure-related differentially expressed genes (DEGs), CVD-related DEGs, and ESRD-related DEGs were identified by differential expression analysis and weighted gene co-expression network analysis. Then, AVF-failure-related, CVD-related, and ESRD-related DEGs were overlapped to obtain the hub genes. The diagnostic values of hub genes were evaluated. Finally, the immune infiltration analysis and drug prediction were performed.</p><p><strong>Results: </strong>A total of four hub genes (ABCC8, ALPI, FGF11, and OBP2A) were identified, and those genes have excellent diagnostic accuracy. Among them, ABCC8, ALPI, and FGF11 showed good sensitivity and specificity. However, compared to the nondiabetic subgroup, the diagnostic ability of these genes was weaker in the diabetic subgroup for distinguishing AVF failure in ESRD patients. Type 17 T helper cells and gamma delta T cells may be associated with CVD caused by ESRD and AVF. A total of 15 drugs associated with hub genes were predicted.</p><p><strong>Conclusion: </strong>ABCC8, ALPI, and FGF11 could serve as potential diagnostic biomarkers for AVF failure and CVD in HD-treated ESRD patients. Their robustness needs to be validated in larger cohorts and additional subgroups with comorbidities.</p>","PeriodicalId":9584,"journal":{"name":"Cardiorenal Medicine","volume":" ","pages":"386-398"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12162112/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Secondary Cardiorenal Syndromes in Children: Focus on Type 3 to 5 Cardiorenal Syndrome.","authors":"Emre Leventoğlu, Akif Kavgacı, Utku Arman Örün, Bahar Büyükkaragöz","doi":"10.1159/000545791","DOIUrl":"10.1159/000545791","url":null,"abstract":"<p><strong>Background: </strong>The interaction between the heart and kidneys involves complex mechanisms, leading to a clinical condition known as cardiorenal syndrome (CRS), where dysfunction in one organ leads to impairment of the other. This syndrome can be acute or chronic, affecting both organs simultaneously.</p><p><strong>Summary: </strong>In 2008, the Acute Dialysis Quality Group classified CRS into two main categories: cardiorenal CRS and renocardiac CRS, based on the primary organ affected. Cardiorenal CRS includes two subtypes where heart failure causes kidney injury (types 1 and 2), while renocardiac CRS (types 3 and 4) refers to kidney injury leading to cardiac dysfunction, either from acute kidney injury or chronic kidney disease. Type 5 CRS is termed as secondary CRS which involves both organ dysfunction due to an acute systemic disease, such as sepsis, infections, or chronic conditions like diabetes mellitus. This review examines the cardiovascular involvement in various nephrological diseases commonly seen in clinical practice, with a focus on types 3-5 CRS in children from a nephrology perspective.</p><p><strong>Key messages: </strong>CRS is common in pediatric patients with cardiac, renal, or systemic conditions and poses a significant risk of mortality. The lack of longitudinal studies or specific biomarkers for the diagnosis, treatment, and follow-up of CRS in children is evident. Aspects such as the development of new biomarkers, ongoing research into neurohormonal mechanisms, meta-analyses, and introduction of algorithms for the follow-up period may reshape patient management. Specific diagnostic tools or therapeutic interventions for CRS management in children should be implemented. Collaborative efforts among pediatricians, cardiologists, and nephrologists are essential for developing effective treatments. Large-scale studies are needed to better understand CRS and develop targeted therapies to improve outcomes for pediatric patients, reducing morbidity and mortality.</p>","PeriodicalId":9584,"journal":{"name":"Cardiorenal Medicine","volume":" ","pages":"358-373"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143953625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Wnt3a/β-Catenin/TCF7L2 Pathway in Diabetes and Cardiorenal Complications.","authors":"Yilinuer Adeerjiang, Abudulimu Sidike, Xiao-Xue Gan, Qin-Tian Li, Sheng Jiang","doi":"10.1159/000543145","DOIUrl":"10.1159/000543145","url":null,"abstract":"<p><strong>Background: </strong>Diabetes mellitus is a prevalent chronic disease that is becoming increasingly common worldwide and can lead to a number of dangerous complications. The Wnt signaling pathway is important for the onset and progression of diabetes. Wnt3a is a typical Wnt ligand that can increase the stability of β-catenin, control TCF7L2 expression, promote β-cell proliferation, and reduce apoptosis.</p><p><strong>Summary: </strong>The involvement of the Wnt3a/β-catenin/TCF7L2 signaling pathway in the development of diabetes and associated problems related to the kidneys is reviewed in this article.</p><p><strong>Key message: </strong>We believe that a thorough comprehension of the molecular connections between diabetes and signaling pathways will eventually lead to improved diabetes management.</p>","PeriodicalId":9584,"journal":{"name":"Cardiorenal Medicine","volume":" ","pages":"72-82"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11844670/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142876240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}